Introduction
Patients suffering from autoimmune disorders are at higher risk of developing accelerated atherosclerosis and cardiovascular events when compared to the general population.
1,2 Beyond classical atherosclerotic risk factors, including family history, 3 arterial hypertension, 4 diabetes mellitus, 5 smoking, 6 physical inactivity, 7 diet, 8 obesity 9 and dyslipidemia, 10 commonly assessed using the Framingham criteria, 11 the 'systematic coronary risk evaluation' checklist or similar cardio-vascular risk calculation charts, systemic or chronic inflammation contributes to the endothelial dysfunction leading to plaque formation and, as such, having an autoimmune disease is being now recognized as a significant risk factor in terms of higher cardiovascular morbidity and mortality. 12 Rheumatic diseases, such as rheumatoid arthritis (RA), 13 ankylosing spondylitis, 2 systemic sclerosis, 14 polymyositis and dermatomyositis, 15 Sjö gren syndrome 16 and systemic lupus erythematosus. 17 confer, indeed, higher susceptibility to cardiovascular events, probably due to the effects of systemic inflammation on blood lipid profile and the formation of autoantibodies.
In particular, RA disease activity, positivity of rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibodies, co-morbidities and extra-articular manifestations have been shown to be predictor of cardiovascular accidents, while tumor necrosis factor (TNF)-blockers and disease modifying anti rheumatic drugs (DMARDs) act as protective factors against the development of cardiovascular disorders, probably reducing inflammation.
1,2
Signs of accelerated atherosclerosis, such as carotid intimamedia thickness (CIMT), coronary calcium content, endothelial dysfunction and arterial stiffness, can be detected in RA patients. From a molecular standpoint, atherosclerosis and RA physiopathology share the same basis, namely the activation of lymphocyte T-cells and mast cells, with the subsequent release and production of pro-inflammatory cytokines like TNF-a and interleukin (IL)-6, as well as increased expression of leukocyte adhesion molecules. 18 These non-invasive markers reflect the effects of several biological mechanisms, such as vessel tone regulation, cell proliferation and inflammatory responses. 19 The impairment of brachial artery flow-mediated dilation (FMD%) in RA patients has attracted the interest of different scholars worldwide, however its association with clinical parameters and laboratory biomarkers has sometimes given rise to contrasting or inconsistent results in the extant literature. Therefore, the present investigation aimed to fill in this gap in knowledge and to further advance the field.
Materials and methods

Patients selection
The present prospective study was done in accordance of the 1964 Helsinki declaration and its later amendments. The investigation received ethical clearance by the local ethics committee of the Baruch Padeh Medical Center and every subject (44 patients and 13 healthy volunteers), after being informed of the purpose of the research, had to sign a written consent form before being formally enrolled to the study. Concerning inclusion/exclusion criteria, only RA patients with an active long standing (more than 12 months) were recruited to the study, whereas RA patients were excluded if having renal failure, type 2 or type 1 diabetes mellitus, documented coronary artery disease and other cardiovascular disorders, or cancer. About 44 patients and 13 healthy subjects were recruited to the study. All patients were examined by an experienced rheumatologist in the outpatient clinic and underwent a detailed assessment of disease activity using a battery of different disease activity scale, such as the DAS-28-CRP, DAS-28-ESR, clinical disease activity index (CDAI) and simplified disease activity index (SDAI). Vascular studies were performed in a quiet room in the early morning hours, fasting, after 3 days of diet without nitrite, coffee or tea.
Vascular study
Brachial artery flow mediated diameter percent (FMD%) change measurement was performed in the morning, in a quiet and dark room and at controlled ambient temperatures between 20 C and 26 C. Studies were conducted after an overnight strict fast of at least 10 h (only water was permitted), with the subject supine, and after 10 min of rest. The subject's right arm was comfortably immobilized in the extending position, allowing for ultrasound scanning of the brachial artery 5-10 cm above the ante-cubital fossa. During each examination, recording of vessel images were followed by inflation of a cuff to a supra-systolic pressure (40-50 mmHg above systolic pressure) for approximately 5 min. Subsequently, the cuff was deflated, and image of the brachial artery diameter was taken and recorded for 3 min. In interpreting the results, a brachial artery FMD% greater than 10% is considered a normal response. Values lower than 10% brachial artery FMD% generally reflect endothelial dysfunction, which means a high likelihood of developing a cardiovascular event in the future. Usually, subjects with negative brachial artery FMD% values (the artery is constricted after stress and not dilated as expected) have the worst prognosis.
Statistical analysis
Before commencing statistical processing and analysis, data were visually inspected for outliers and normality of data distribution was checked using the Shapiro-Wilk test. Continuous data were presented as mean 6 standard deviation (SD), whereas categorical variables were computed as percentages.
Clustering analysis was performed in two subsequent steps: namely, hierarchical and k-means clustering techniques.
Figures with P-values less than 0.05 were considered statistically significant. All statistical analyses were performed with a commercial software, namely the Statistical Package for Social Science (SPSS version 24.0, IBM, Chicago, IL, USA).
Results
Forty-four RA patients participated in the present study. Average age was 54.42 6 11.14 years, most subjects were female (72.7%), with co-morbidities (70.5%), not taking TNF-blockers or DMARDs (63.6%). Average CDAI and SDAI values were 14.98 6 8.27 and 16.51 6 9.52, respectively. DAS-28-CRP was 3.73 6 1.13, whereas DAS-28-ESR 4.50 6 1.20. inflammatory markers resulted 10.35 6 13.85 mg for CRP and 29.13 6 21.53 mm in the first hour for ESR. RF was positive in 26 subjects (59.1% of the sample), whereas anti-CCP antibodies could be detected in 25 (56.8%) patients. Average brachial artery FMD% resulted 0.48% (SD 12.82%). Only 6 (13.6%) subjects reported brachial artery FMD% values greater than 10 (normal response). Eighteen (40.9%) subjects presented negative values of brachial artery FMD%. Further details are reported in Table 1 .
Thirteen healthy subjects served as the control group for validation of the brachial artery method of endothelial function estimation (mean age 35.4 6 9.2 years old, with a BMI of 25.4 6 4.1, C reactive protein of 0.27 6 0.21 mg, with a FMD% change of 20.25 6 8.2%).
Hierarchical clustering techniques suggested the threegroup solution as optimum (Figure 1) . Following a k-means iterative solution external validity analysis for the three clusters was considered. Results showed statistically significant differences among the three clusters concerning DAS-28-ESR (P ¼ 0.000), DAS-28-CRP (P ¼ 0.001), CDAI (P ¼ 0.002), SDAI (P ¼ 0.001), ESR (P ¼ 0.000), CRP (P ¼ 0.003) and FMD% (p¼.009) ( Table 2 ). The group with the highest FMD% values exhibited the lowest values for both clinical scores and laboratory parameters. Intriguingly, the patients with the lowest FMD% values co-clustered with subjects with positive but low FMD% changes and elevated clinical and laboratory parameters. Noteworthy, the latter individuals were younger, even though this did not reach statistical significance.
Discussion
The present study found a statistically significant association between FMD% and different RA-related clinical parameters and laboratory biomarkers.
In the extant literature, some studies have not found any differences in brachial artery FMD% between RA patients and the general population. For instance, Van Doornum and coworkers recruited 25 RA patients and 25 matched healthy controls. Authors could not find statistically significant differences in FMD% values between the two groups (P ¼ 0.49). 20 Nevertheless, other scholars have found statistically significant association. For example, Fan and coworkers recruited 102 RA controls, age-and gender-matched with 46 healthy controls. 21 Authors found that the CIMT was significantly higher in patients, whereas brachial artery FMD% was lower in patients, as expected. Brachial artery FMD% correlated only with systolic blood pressure. Similar findings were found by Veselinovic and collaborators, 22 who investigated a sample of 52 RA patients and 30 matched healthy controls. Authors found that CIMT was significantly higher in RA patients and FMD was significantly lower in RA patients. RA patients who used low doses of corticosteroids had better brachial artery FMD% values. Ahmad and colleagues found that 50 RA patients (50.0% of the sample) who had evidence of subclinical atherosclerosis as compared to the control group (n ¼ 11, 11% of the control sample). 22 Low HDL levels, advanced patient age, longer disease duration, greater Furthermore, recently, Xu and colleagues performed a metaanalysis and synthesized ten studies concerning flow-mediated dilatation in RA patients. 25 The results showed that the RA Egger's test (P ¼ 0.004) and the visual inspection of the skewed/ asymmetrical shape of the funnel plot indicated that publication bias existed. Despite some inconsistencies, RA patients should be carefully evaluated and assessed for subclinical peripheral artery disease, even in the early stage of the disease. 26 Brachial artery FMD% has been shown to be a valuable tool and, since this noninvasive index has been shown to correlate with endothelial dysfunction, which is one of the earliest, potentially reversible, manifestations of cardiovascular disorders, physicians can introduce effective, adequate cardiovascular protection measures. 27 Future studies should also consider different noninvasive surrogate techniques 27 or other markers, such as micro-albuminuria, 28 to detect sub-clinical atherosclerosis.
Moreover, monitoring arterial stiffness and other indicators of early atherosclerosis could also serve to verify the effectiveness and appropriateness of medications against RA.
29-31
Study limitations
While our study has several strengths, most notably the systematic assessment of association between brachial artery FMD% and different commonly used clinical scores and laboratory parameters. On the other hand, it suffers from some limitations, including the study design (it is not a randomized control trial and the studied cohort was based on a convenience sample) and its small sample size.
Conclusions
Patients suffering from autoimmune disorders, such as RA, may suffer from accelerated atherosclerosis, due to the intense systemic inflammation. Our study confirms the feasibility of exploiting endothelial function using the brachial artery method (FMD%) in clinical practice as an early predictor of accelerated atherosclerosis. Interestingly, endothelial function was inversely correlated with RA disease severity and may be used as another parameter in the clinical evaluation of disease severity in RA. Larger high-quality studies are needed to replicate our findings in a more robust way.
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